New survey findings from the American Society of Health-System Pharmacists (ASHP) shows that roughly 99% of health-system pharmacists said they are experiencing drug shortages. Nearly one-third of the respondents said the current shortages are “critically impactful,” causing facilities to delay, ration, or cancel procedures or treatments.

A new study in JAMA Network Open found that as drug overdose deaths have reached unprecedented levels in the United States, evidence-based treatments for substance use are severely underused.

In July, FDA approved nirsevimab-alip (Beyfortus—Sanofi/AstraZeneca). A few weeks later, on August 3, 2023, CDC’s ACIP voted unanimously to recommend the broad use of the new drug to infants and high-risk children for protection against respiratory syncytial virus (RSV).